Pravin Dugel, MD

Novel brolucizumab fosters as real-world alternative for nAMDTopline results from phase III studies investigating intravitreal brolucizumab (Novartis) for treatment of neovascular age-related macular degeneration (nAMD) support the potential of this novel anti-VEGF antibody to meet the real-world need for an alternative agent with a sustainable therapeutic regimen.
27-gauge presents new paradigm of intraocular precision for vitrectomyModern 27-gauge equipment for vitrectomy has introduced a new paradigm in vitreoretinal surgery marked by enhanced precision and control.
Anti-PDGF inhibitor development continues despite negative resultsDespite the failure of 2 clinical trials involving a combination therapy of platelet-derived growth factor (PDGF) inhibitor and anti-vascular endothelial growth factor (anti-VEGF) therapy, a third phase III study continues.
DARPin molecule prolongs anti-VEGF activity in nAMDA phase III study program investigating abicipar pegol (Allergan) for the treatment of neovascular age-related macular degeneration (nAMD) is underway based on promising efficacy and safety results in phase II studies.
First three injections predict success of anti-VEGFs in diabetic macular edemaWhile it is still unclear why some patients respond well to anti-VEGF therapy and others do not, a new post hoc analysis of the Protocol I data may help physician make more efficient use of therapy by more quickly identifying which category each patient is in.
New vitrectomy technologies advance precision, efficiency during surgeryA retina specialist explains why vitrectomy surgery is safer and more efficient using a new ultra-high-speed vitrectomy cutting probe combined with 27+ gauge instrumentation.
Anti-VEGF therapy: Identifying safety trendsAnalyses of data from large clinical trials have been undertaken to determine how patient age and treatment-specific variables may influence the systemic safety of anti-vascular endothelial growth factor treatment.
How emixustat hydrochloride may help geographic atrophyDrug modulates visual cycle activity, reduces oxidative stress, slows accumulation of toxins
Combination therapy a boon for AMD